Owlstone Medical wins up to $49.1 million award from ARPA-H to develop at-home multi-cancer-early detection tests

Goal of POSEIDON is to enable accurate, low-cost, accessible cancer screening for all AmericansProgram to deliver first-in-class synthetic-sensor based MCED test for Stage I detection of 30+ solid tumorsOwlstone to work in partnership with the Massachu

Owlstone Medical announces investment of up to $2.3 Million USD from the Cystic Fibrosis Foundation to develop a breath test for Pseudomonas aeruginosa detection in Cystic Fibrosis patients

Test to be developed for Pseudomonas aeruginosa detection in patients with cystic fibrosis suitable for both detection of new cases and monitoring of chronic infection Support to demonstrate proof of principle in chronic infection to be provided to Owlstone in the

Owlstone Medical announces $27 Million USD first close in Series E financing round

Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of Breath Biopsy diagnostic tests and point of care devices fo

OMED Health collects Gold award for Website of the Year

On Friday 6th December the National SME Business Awards took place at Wembley Stadium. The event pulled together the regional winners, with a Gold and Silver award presented in each category.

Owlstone Medical partners with the FDA to advance the identification of volatile organic compounds in breath and expand its Breath Biopsy VOC Atlas.

Collaboration will develop analytical methods to improve the identification of specific chemicals in complex gaseous mixtures Owlstone will use the developed methods and techniques to enhance its work in the field of breath-based biomarkers of disease

Owlstone Medical celebrates success at SME Cambridgeshire Business Awards

It was a double success as the Owlstone Medical team scooped two awards. The company won Website of the Year for its OMED Health website and silver for Employer of the Year.

Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease

$5 million equity investment and initial $1.5 million grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding represents the first time the foundation has taken an

Owlstone Medical presents data demonstrating progress in development of Breath Biopsy tests for Liver Cirrhosis and NASH

Data presented at EASL Congress 2023, Austria, 21-24 June Findings support the use of limonene as an EVOC® probe for the detection of cirrhosis, and demonstrate correlation with disease severity

Cambridge, UK, June 22, 2023:

Owlstone Medical presents data demonstrating progress in development of breath biopsy test for the early detection of lung cancer

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announces new data on the development of a screening test for the early detection of lung cancer.

Owlstone Medical wins contract from U.S. Department of Defense to develop handheld breath biopsy device for early infectious disease detection

Initial award recognizes potential of proprietary Owlstone Medical technology for non-invasive viral and bacterial respiratory infectious disease detection Goal of the project is to provide a device to every warfighter in the field where access to diagnostic testing

Owlstone Medical launches OMED Health to enable patients to better understand their gut microbiome and manage their digestive health

Breath-based analysis technology and digital platform offers a science-backed approach to helping individuals monitor and treat their gut health and understand their microbiome Supported by gastrointestinal experts, information can be used to develop a personalised

Owlstone Medical enters partnership with Bicycle Therapeutics for the development of Antigen-Targeted EVOC Probes for early Cancer detection

Cambridge, UK - Owlstone Medical , the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announces that it has entered into a Research Agreement with Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology.

Owlstone Medical publishes data on the use of exhaled volatile organic compounds as biomarkers for liver disease detection

Study published in Journal of Clinical and Translational Hepatology demonstrates alterations in breath VOCs can be used to differentially identify liver disease on breath  Builds upon previous publication, identifying limonene as a breath biomarker to measure liver function

Owlstone Medical launches Breath Biopsy VOC Atlas

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the launch of the Breath Biopsy VOC Atlas, a catalogue of validated and quantitated volatile organic compounds (VOCs) found on breath.

Owlstone Medical appoints Mark Capone to Board of Directors

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the appointment of Mark Capone, former President and CEO of Myriad Genetics, to its Board as an independent non-executive director. Following this appointment, the Owlstone Medical Board comprises seven members including one executive director and two…

Owlstone Medical closes £42m oversubscribed financing round to continue to advance breath biopsy

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the close of its Series D financing round. Due to the high level of interest in this capital raise, the company has significantly exceeded its $50 million target, securing $58 million in funding (c. £42 million) and bringing the total raised by the Company to…

Owlstone Medical publishes data on the use of face mask filters to capture viral particles for SARS-CoV-2 detection

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the publication of a peer-reviewed study in 'Nature Scientific Reports'1. The paper investigates the performance of filters embedded in face masks for supporting the detection of SARS-CoV-2 as an alternative to nasopharyngeal swabs (NPS).

Owlstone Medical's annual Breath Biopsy Conference is online this autumn

Owlstone Medical's next Breath Biopsy Conference (BBCon21) will be held on the 12th & 13th October.  The firm is keen to keep reaching global audiences, and this year’s event will be online and free to attend. Registration is open now.

Owlstone Medical launches breath testing for digestive health

Owlstone Medical (OML), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced agreements with Functional Gut Clinic (FGC) and Functional Gut Diagnostics (FGD), leading providers of smart solutions for the diagnosis of gut health problems.

Owlstone Medical introduces Breath Biopsy Panel for respiratory diseases

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today introduced the Respiratory Diseases Research Use Only (RUO) Panel.

7 highlights from 2020: An exciting year of progress for Owlstone Medical

2020, as a consequence of COVID-19, has seen a greatly increased level of international interest in the fast-growing field of breath research. As this globally challenging year is now at an end, Owlstone Medical has taken a look back at what it has achieved for Breath Biopsy®.

Owlstone Medical expands US operations and establishes permanent US office

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announces that it has taken important steps to better support its pharmaceutical and academic customers in the United States by establishing a permanent office and expanding its highly skilled local team.

Owlstone Medical announces key study results on use of breath biopsy for improved detection of liver disease

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the results of a patient study that successfully demonstrates the use of exhaled limonene as a breath biomarker to measure liver function and stage liver disease.

Owlstone Medical appoints Neil Tween as Chief Financial Officer

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announces the appointment of Neil Tween as its new Chief Financial Officer.

Owlstone Medical named as one of FierceMedTech’s “Fierce 15” companies of 2019

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it has been named by FierceMedTech as one of 2019’s Fierce 15.